Navigation Links
Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Date:2/6/2008

f endometriosis is pelvic pain. The pain often correlates to the menstrual cycle, but a woman with endometriosis may also experience pain that doesn't correlate to her cycle. For many women, the pain of endometriosis is so severe and debilitating that it impacts their daily lives in significant ways.

It is estimated that seven to 10 percent of all women are affected by endometriosis, including 70 to 87 percent of women with chronic pelvic pain and 30 to 40 percent of all infertile women. Chronic pelvic pain, dysmenorrhea (painful periods) and dyspareunia (painful intercourse) are common symptoms of women with endometriosis. There are several medical treatment options, including danazol, GnRH agonists and progestins, each of which have limitations associated with patient response, tolerability, side- effect profile and duration of treatment.

"I am pleased that Meditrina will be pursing this indication, leveraging the work done to date by AstraZeneca. Anastrozole in combination with an estrogen and progestin in the area of women's gynecologic indications represents a valid medical approach and sits well with Meditrina's strategic focus and expertise," commented Dr. John Patterson, Executive Director, Research and Development, AstraZeneca.

Terms of the agreement were not disclosed.

About Meditrina Pharmaceuticals, Inc.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs. By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina's novel therapies have the potential to significantly alter the way these women's health conditions are treated. For more information about Meditrina Pharmaceuticals, please visit

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
8. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
11. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
(Date:7/10/2014)... our laptops and electric vehicles could store more energy ... help of a sponge-like silicon material. , Researchers ... used in one of the battery,s electrodes, as silicon ... of graphite. A paper describing the material,s performance as ... Nature Communications . , "Silicon has long been sought ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... Rising star Divine Skin Inc. (DSKX), which has been expanding ... long-time leader in the cosmetics industry, to become its president. ... Divine Skin because I believe their innovative products are unmatched ... with a ,wow, factor." A dozen Divine ...
... 25, 2011 For the first time, Eli Lilly and ... to more than 800 grassroots projects across the globe and ... Foundation—doubling the value and impact of each employee,s charitable contribution. ... to offer its employees across the world a customized Lilly ...
... Sciences International, Inc. (Nasdaq: BDSI ) announced ... portion of its Phase 3 clinical trial assessing the ... of moderate to severe chronic pain, signifying completion of ... are very pleased to have brought to completion our ...
Cached Biology Technology:Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 3Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 4BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... a part of the National Institutes of Health ... million to fund three new Institutional Development Awards ... concentrating on one general area of research ... research infrastructure. The IDeA program is designed to ...
... altering the Earths chemistry. Many of societys most pressing ... from human activities that disrupt natural chemical cycles. Moving ... reversing actions that have such a huge impact on ... of the Institute of Ecosystem Studies, Dr. William H. ...
... -- Three researchers at the Albert Einstein College of ... Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and ... its ongoing effort to support the advancement of breast ... is its mission, which is to achieve prevention and ...
Cached Biology News:NIH grants $33 M in institutional development awards to 3 states 2Biogeochemistry -- A window into the Earth's ecological health 2Einstein researchers receive grants totaling $700,000 for innovative breast cancer research 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Biology Products: